Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06338826 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

Study acronym: BI-LIGHT
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Oct 1, 2024 to Feb 1, 2025v3
  2. Primary and study completion dates: Feb 28, 2027 to Sep 30, 2027
    • Start date: May 1, 2024 to Oct 1, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy
Trial Details
NCT Number NCT06338826
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions
(from sponsor)		 HIV Infections, HBV Coinfection
Related terms HIV Infections
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov